Letters to the Editor

Risks Related to the Use of Finasteride (Propecia) in Pregnant Women


Am Fam Physician. 2010 Jul 15;82(2):102.

Original Article: Polycystic Ovary Syndrome [Clinical Evidence Handbook]

Issue Date: September 15, 2009

Available at: https://www.aafp.org/afp/2009/0915/p579.html

to the editor: In the Clinical Evidence Handbook on polycystic ovary syndrome (PCOS), the author discusses the off-label use of finasteride (Propecia) to reduce hirsutism in patients with PCOS. It should be emphasized that finasteride is not indicated for use in women, and is classified by the U.S. Food and Drug Administration as pregnancy risk Category X. According to the finasteride product information: “Abnormalities of external male genitalia were reported in animal studies. Pregnant women are advised to avoid contact with crushed or broken tablets.”1 Many patients with PCOS suffer from infertility; however, many of these patients regain fertility as a result of their medical treatments. Women who choose to take finasteride for hirsutism related to PCOS should be informed of the potential risks associated with this treatment and take precautions to prevent an unplanned pregnancy.

Author disclosure: Nothing to disclose.


1. Finasteride. Drug information provided by Lexi-Comp. Merck Manuals Online Medical Library for Healthcare Professionals. http://www.merck.com/mmpe/print/lexicomp/finasteride.html. Accessed April 19, 2010.

In reply: Thanks to Dr. Keller for his recent letter regarding the safety of finasteride (Propecia), and particularly the lack of specific reference to the risks of taking an antiandrogen medication in women at risk of pregnancy, and the concomitant risks to a male fetus. Dr. Keller is, of course, correct. The prescription of finasteride to women of child-bearing age should be accompanied by counseling on the use of effective contraceptive methods.

Author disclosure: Nothing to disclose.

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.



Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Apr 1, 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article